Glauconix Biosciences, Inc.
George Torrejon began their work experience as the Senior Director of Operations & Business Development at Glauconix Biosciences, Inc. in July 2016. George played a crucial role in utilizing bio-engineered human trabecular meshwork (HTM) technology for discovering glaucoma therapeutics.
In June 2017, Torrejon transitioned to the University at Albany, SUNY, where they worked as a Business Development Manager until May 2018.
Prior to that, Torrejon worked as an Internal Auditor at Broadridge Investment Accounting (Formerly QED Financial Systems) from March 2014 to May 2016.
From 2008 to 2013, George Torrejon attended the University at Albany, SUNY. During this time, they pursued a Bachelor of Science degree in Applied Economics.
This person is not in any teams
Glauconix Biosciences, Inc.
www.glauconix-biosciences.com Glauconix Biosciences is a specialty pharma research company that uses an innovative platform technology to reduce the cost of ophthalmic drug development. Glauconix operates out of its laboratories located at the SUNY Polytechnic Institute-Albany, NY campus. We collaborate with academic and industry partners to help screen, identify and validate the unique MOA of the most effective drug candidates. Glauconix’s 3D tissue system can reduce the risk of clinical trial failure; saving time, labor and development costs. Early identification and validation of effective compounds or biologics, allows partners to confidently enter clinical trial.